Study of Novel Treatment Combinations in Patients With Lung Cancer

Key Inclusion Criteria:

All Substudies:

Histologically or cytologically documented non-small-cell lung cancer (NSCLC) with evidence of stage IV disease.
No known actionable genomic alterations for which approved therapies are available.
Eastern cooperative oncology group (ECOG) performance status score of 0 or 1.
Measurable disease as per response evaluation criteria in solid tumors (RECIST) 1.1 criteria.
Adequate hematologic and end-organ function.
Individuals of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception.

Substudy 01: All Experimental arms

For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alteration negative.
No prior systemic treatment for metastatic NSCLC.

Substudy 02: All Experimental arms

In individuals with nonsquamous histology, individuals with EGFR, ALK, or any other known actionable genomic alterations must have received treatment with at least 1 approved tyrosine kinase inhibitor (TKI) appropriate to the genomic alteration.
Progression or disease recurrence after platinum-based chemotherapy with anti-PD-1 or anti-PD-L1 antibody OR sequential treatment (in any order).

Key Exclusion Criteria:

All Substudies:

Mixed small-cell lung cancer and NSCLC histology.
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Received previous anticancer therapy within 4 weeks prior to enrollment.
Active second malignancy.
Active autoimmune disease.
History of or current non-infectious pneumonitis/interstitial lung disease.
Active serious infection within 4 weeks prior to study treatment.

Note: Other protocol defined inclusion/exclusion criteria may apply